{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:51Z","timestamp":1787628111323,"version":"build-2736575974"},"reference-count":43,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kite, a Gilead Company"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2079317","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T08:54:26Z","timestamp":1653468866000},"page":"730-740","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed\/refractory mantle cell lymphoma post BTKi in England"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5058-7645","authenticated-orcid":false,"given":"Svenja","family":"Petersohn","sequence":"first","affiliation":[{"name":"OPEN Health, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-4601","authenticated-orcid":false,"given":"Jim","family":"Wu","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4726-7995","authenticated-orcid":false,"given":"Sally W.","family":"Wade","sequence":"additional","affiliation":[{"name":"Wade Outcomes Research and Consulting, Salt Lake City, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-7261","authenticated-orcid":false,"given":"Claire L.","family":"Simons","sequence":"additional","affiliation":[{"name":"OPEN Health, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-5510","authenticated-orcid":false,"given":"Craig","family":"Bennison","sequence":"additional","affiliation":[{"name":"OPEN Health, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-1531","authenticated-orcid":false,"given":"Rubina","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Peng","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Kloos","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-6453","authenticated-orcid":false,"given":"Gab","family":"Castaigne","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-5688","authenticated-orcid":false,"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Pneumology University Medical School of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15283"},{"key":"e_1_3_4_4_1","unstructured":"NICE. Non-Hodgkin\u2019s lymphoma: diagnosis and management [NG52]. 2016."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2596"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198812"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097721"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0537-5"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15025"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15170"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"e_1_3_4_12_1","volume-title":"Management of relapsed\/refractory mantle cell lymphoma (MCL) in routine clinical practice in Spain (IMORS study)","author":"Reyes Arranz","year":"2018","unstructured":"Reyes Arranz Jose Luis B, Miguel \u00c1ngel C, et\u00a0al. editors. Management of relapsed\/refractory mantle cell lymphoma (MCL) in routine clinical practice in Spain (IMORS study). Descriptive Data and Efficacy Results; 2018. Available from: https:\/\/library.ehaweb.org\/eha\/2018\/stockholm\/216049\/reyes.arranz.management.of.relapsed.refractory.mantle.cell.lymphoma.28mcl29.in.html?f=menu=6*ce_id=1346*ot_id=19046*media=3*marker=168"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17363"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125947"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","unstructured":"Wang ML Munoz J Goy A et\u00a0al. editors. KTE-X19 an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy in Patients (Pts) With Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. ASH; 2019. Blood.","DOI":"10.1016\/j.bbmt.2019.12.135"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139063"},{"key":"e_1_3_4_18_1","unstructured":"NICE. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma. 2021."},{"key":"e_1_3_4_19_1","unstructured":"NICE Decision Support Unit. NICE DSU Technical Support Document 19 Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review; 2017."},{"key":"e_1_3_4_20_1","volume-title":"KTE-X19 versus standard of care for relapsed\/refractory mantle cell lymphoma previously treated with Bruton tyrosine kinase inhibitors: Real-World evidence from Europe","author":"Hess G","year":"2021","unstructured":"Hess G, Dreyling M, Oberic L, et\u00a0al. editors. KTE-X19 versus standard of care for relapsed\/refractory mantle cell lymphoma previously treated with Bruton tyrosine kinase inhibitors: Real-World evidence from Europe. EHA; 2021."},{"key":"e_1_3_4_21_1","unstructured":"Dreyling M Shah B Wu JJ. et al. Efficacy Outcomes Following Treatment with BTKi for Relapsed\/Refractory Mantle Cell Lymphoma (R\/R MCL): A Literature-Based Meta-Analysis. Abstract accepted ISPOR library; 2022-05;SA29 [Internet]. Available from: https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/intl2022-3461\/116051"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.06.010"},{"key":"e_1_3_4_23_1","unstructured":"NICE. Guide to the methods of technology appraisal 2013. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781."},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1894158"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"e_1_3_4_26_1","unstructured":"NICE. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies [ID1115]. 2018."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_3_4_28_1","unstructured":"NICE. Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma [ID1166]: Committee Papers. 2018."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1529674"},{"key":"e_1_3_4_30_1","volume-title":"CAR-T therapies: final evidence report","author":"ICER","unstructured":"ICER. CAR-T therapies: final evidence report. [Internet]; ICER. 2018 [cited 2021 Dec 9]. Available from: https:\/\/icer-review.org\/material\/car-t-final-report\/."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9876.2009.00677.x"},{"key":"e_1_3_4_32_1","volume-title":"NICE DSU technical support document 21","author":"Rutherford MJ","unstructured":"Rutherford MJ, Lambert PC, Sweeting MJ, et\u00a0al. NICE DSU technical support document 21. Flexible Methods for Survival Analysis. [Internet]; 2020 [cited 2021 Dec 14]. Available from: http:\/\/nicedsu.org.uk\/."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"e_1_3_4_34_1","unstructured":"British National Formulary. [Internet]; [cited 2021 Oct 8]. Available from: https:\/\/bnf.nice.org.uk."},{"key":"e_1_3_4_35_1","unstructured":"NHS. NHS National Reference Cost schedule 2018-19 2019. Available from: https:\/\/www.england.nhs.uk\/national-cost-collection\/#ncc1819."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_3_4_37_1","unstructured":"NICE. Ibrutinib for treating relapsed or refractory mantle cell lymphoma. Technology appraisal guidance [TA502] \u2013 Committee Papers. 2016."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012576"},{"key":"e_1_3_4_39_1","unstructured":"Curtis LA Burns A. Unit Costs of Health and Social Care 2020; 2021. Available from: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2020\/."},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x"},{"key":"e_1_3_4_41_1","unstructured":"Hettle R Corbett M Hinde S et\u00a0al. Review of cost-effectiveness evidence for chimeric antigen receptor T-cell therapy and other interventions for acute lymphocytic leukaemia. [Internet]. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review economic evaluation and appraisal. NIHR Journals Library. 2017 [cited 2021 Aug 11]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK424721\/."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy193"},{"key":"e_1_3_4_43_1","unstructured":"Liu R Snider JT Diakite I Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucal (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (RR LBCL) in the US. EHA library; 06\/12\/20; 294211; EP1731. 2020 et\u00a0al. 2020."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000524"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2079317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:24:48Z","timestamp":1729164288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2079317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2079317"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2079317","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}